LXEO
NASDAQLexeo Therapeutics Inc.
News25/Ratings11
News · 26 weeks49+100%
2026-03-012026-08-23
Mix2790d
- Insider14(52%)
- Other9(33%)
- SEC Filings4(15%)
Latest news
25 items- INSIDERChief Financial Officer Tamayo Louis Edward sold $20,203 worth of shares (4,117 units at $4.91), decreasing direct ownership by 4% to 92,907 units (SEC Form 4) (tax withholding)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Executive Officer Townsend Richard Nolan sold $16,562 worth of shares (3,345 units at $4.95), decreasing direct ownership by 0.89% to 374,472 units (SEC Form 4) (withholding tax)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Operating Officer Otero Jose Manuel sold $6,464 worth of shares (1,304 units at $4.96), decreasing direct ownership by 0.95% to 136,178 units (SEC Form 4) (for tax liability)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- SECSEC Form 10-Q filed by Lexeo Therapeutics Inc.10-Q - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- SECLexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- PRLexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational HighlightsFinalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment continues to advance, supporting identification of eligible participants for SUNRISE-FA 2 FDA granted RMAT designation for LX2020 based on recent interim clinical data in PKP2-ACM Cash, cash equivalents and investments of $234.2 million expected to provide operational runway into 2028 NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genet
- SECSEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)
- PRLexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic CardiomyopathyRMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM LX2020 now holds RMAT, Orphan Drug and Fast Track designations by the FDA NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to LX2020, the Company’s investigational AAV-based gene therapy candidate for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). RMAT
- INSIDERChief Financial Officer Tamayo Louis Edward was granted 12,000 shares and sold $20,838 worth of shares (4,641 units at $4.49), increasing direct ownership by 8% to 97,024 units (SEC Form 4) to cover taxes4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Operating Officer Otero Jose Manuel sold $20,904 worth of shares (4,666 units at $4.48) and was granted 12,060 shares, increasing direct ownership by 6% to 137,482 units (SEC Form 4) (withholding obligation)4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Medical Officer Bhalla Narinder Pal was granted 55,000 shares and sold $98,593 worth of shares (22,306 units at $4.42), increasing direct ownership by 66% to 82,194 units (SEC Form 4) to cover withholding tax4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERChief Executive Officer Townsend Richard Nolan was granted 67,000 shares and sold $116,243 worth of shares (25,947 units at $4.48), increasing direct ownership by 12% to 377,817 units (SEC Form 4) to satisfy withholding tax4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- SECLexeo Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
- INSIDERSEC Form 4 filed by Director Altschuler Steven4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERSEC Form 4 filed by Director Agger Mette Kirstine4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERSEC Form 4 filed by Director Cooperstone Brenda4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERSEC Form 4 filed by Director Diaz Reinaldo M4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERSEC Form 4 filed by Director Tanguler Tolga4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERSEC Form 4 filed by Director Van Hauwermeiren Timothy4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- INSIDERSEC Form 4 filed by Director Cholmondeley Paula H4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
- PRLexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich AtaxiaPublished findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027 NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that key results from Phase I/II studies of LX2006 gene therapy in Friedreich ataxia (FA) have been published in the Journal of the American Medical Association (JAMA) Cardiology, linked here.JAMA Cardiology Publication The assessment of s
LXEO FAQ
6 questionsWhere does LXEO stock trade?
Lexeo Therapeutics Inc. (LXEO) is listed on NASDAQ.What sector and industry is LXEO in?
Lexeo Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Lexeo Therapeutics Inc. go public?
Lexeo Therapeutics Inc. (LXEO) completed its IPO in 2023.What are analysts saying about LXEO?
Lexeo Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $2500.00 price target on 2025-12-18. Recent price targets range from $1900.00 to $3000.00.What companies are similar to LXEO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare LXEO side-by-side with any of them on Quantisnow.How can I track LXEO on Quantisnow?
Quantisnow aggregates Lexeo Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LXEO to receive live email and push alerts on every new disclosure.